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REVIEW
Non-canonical WNT/PCP signalling in cancer: Fzd6 takes
centre stage
G Corda1,2,4 and A Sala1,2,3
Frizzled receptors are the mediators of the wnt canonical and non-canonical pathways, which play fundamental roles in cell
differentiation and organism development. A large body of work indicates that dysregulation of wnt signalling is a feature of
oncogenic transformation, but most of the studies published so far focus on the assessment of the consequences of aberrations of
the canonical pathway in human cancer. In this review, we discuss the emerging role of the wnt non-canonical pathway regulated
by frizzled receptor 6 (Fzd6) in the pathogenesis of different types of human malignancies. The function played by Fzd6 in the
physiology of normal and cancer cells has been highlighted in the view that an increased knowledge of the signalling pathways
upstream and downstream of this receptor could ultimately result in the identification of new targets for cancer therapy.
Oncogenesis (2017) 6, e●●; doi:10.1038/oncsis.2017.69; published online xx xxx 2017
INTRODUCTION
Frizzled receptors (FZDs) are seven-transmembrane-spanning
proteins belonging to a sub-class of the G protein-coupled
receptor family.1 In humans, there are 10 FZD receptors each
encoded by a separate gene. Interaction of wnt ligands with FZDs
results in the activation of the canonical or non-canonical wnt
signalling pathways regulating embryonal development, cell
proliferation, motility, polarity, stem cell maintenance and tissue
differentiation.2 The main molecules involved in the canonical and
non-canonical pathways are illustrated in Figure 1. Despite recent
advances in the understanding of the function of FZDs and wnts,
some aspects of the wnt pathway are still poorly understood. This
is probably a consequence of the intricate connections between
the 19 wnt ligands and the 10 FZDs, making the signalling
pathway an intrinsically complicated system to study. Classically,
activation of the wnt canonical pathway leads to the stabilization
and translocation of β-catenin into the cell nucleus, where it
promotes the transcription of wnt-associated genes.3 The term
non-canonical pathway refers to a group of wnt-dependent
signalling pathways which do not lead to the cytoplasmic
stabilization of soluble β-catenin. Two of these pathways have
been well characterized: the planar cell polarity (PCP) and the wnt-
Calcium pathway. Although, for simplicity, wnt signalling is often
dichotomized in two branches, the canonical and the non-
canonical pathways often overlap to coordinate complex cellular
responses.
Nusse and Varmus were the first to observe that MMTV (mouse
mammary tumour virus) infection induces mammary tumours in
mice through activation of the WNT1proto-oncogene.4 Since then,
many distinct alterations in the wnt pathway have been related to
carcinogenesis and tumour development. Deregulated expression
or mutations of FZDs genes have been observed in various human
malignancies, indicating the prominent role of these signalling
molecules in cancer.5–12
PHYSIOLOGY OF FRIZZLED RECEPTOR 6
Frizzled receptor 6 (Fzd6) is a 706 amino acid, 7 transmembrane
domain receptor, encoded by the FZD6 gene, located in
chromosome 8 (8q22.3-q23.1). Similarly, to other FZD receptors,
Fzd6 contains an extracellular cysteine-rich domain, the binding
site for wnt proteins13 and Soluble Frizzled-related proteins.14 In
contrast to other members of the Fzd family, Fzd6 does not
contain a second C-terminal PDZ domain-binding motif15
(Figure 2).
Fzd6 has been shown to regulate both canonical and non-
canonical pathways, but most reports indicate a prevalent role in
the non-canonical pathway.
Golan and collaborators observed that the ectopic expression of
FZD6 in HEK293 cells did not result in the activation of the
canonical pathway, even in the presence of canonical ligands.
Conversely, the ectopic expression of FZD1 led to a significant
activation of the canonical pathway in similar conditions. The
group identified Fzd6 as an inhibitor of the canonical pathway
through activation of TAK1/NLK kinases, which in turns reduce
activation of β-catenin target genes via phosphorylation of TCF/
LEF transcription factors.16 These early results indicated that Fzd6
could be upstream of the wnt/Calcium pathway. Accordingly,
studies on canine kidney epithelial cells demonstrated that Fzd6
physically binds to the canonical ligand wnt4, but ectopic
expression of FZD6, together with WNT4, did not induce any
greater wnt4-dependent activation of TCF/LEF reporter, suggest-
ing a non-canonical role for Fzd6 in this system.17 Interaction of
Fzd6 with wnt4 was also observed in murine hematopoietic
precursor cells; depletion of Fzd6 abrogates the wnt4 dependent
expansion of these cells, suggesting that the receptor is critically
required for wnt4 function.18 In another study conducted in
HelaS3 cells it was reported that downregulation of FZD6 did not
change accumulation of nuclear β-catenin, nor the activation of
RAC following stimulation with the canonical ligands wnt3a or
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wnt5a, further suggesting a non-canonical role of the receptor.
The same study also revealed that the Fzd6 cysteine-rich domain
does not bind to wnt3a and wnt5a.19 A FRAP assay was conducted
to identify Fzd6 ligands by measuring the membrane shift of Fzd6
following stimulation with different wnts. The analysis indicated
that Fzd6 binds to wnt3a, wnt4, wnt1, wnt5a, wnt9b, wnt10b and
wnt16b. However, this technique cannot discern between direct
and indirect binding, and there is the possibility that the different
ligands interact with other receptors in the proximity of Fzd6.20
In spite these and other studies suggest an involvement of Fzd6
with the non-canonical pathway, other reports indicate otherwise.
For example, it was observed that Fzd6 signalling activates β-
catenin in a study of patients affected by nail dysplasia caused by
germline FZD6 mutations.21 This study reported that wnt3a
signalling causes β-catenin accumulation in healthy, but not
FZD6-mutant, fibroblasts, indicating a canonical role of Fzd6 in this
context. Interestingly, a recent paper revealed that Fzd6 interacts
with the heterotrimeric proteins Gαi1/Gαq and that the complex is
dissociated following the stimulation with wnt5a.22 However, the
G-protein-mediated signalling cascade downstream of Fzd6 and
its putative role in disease and cancer remains largely obscure.
Fzd6 might also mediate cellular signals through the activation of
the c-Jun N-terminal Kinase (JNK), since Fzd6high neuroblastoma
stem cells contain higher levels of phosphorylated JNK compared
to the Fzd6 negative counterparts.23 JNK is required for
convergent extension movements that characterize gastrulation
in frogs, controlled by Wnt/PCP signalling, suggesting that Fzd6
could potentially regulate PCP and JNK activation.24
The physiological function of FZD6 is inferred by the analysis of
genetic disorders that have been linked to mutations of the locus.
For instance, there is a strong correlation between frameshift
mutations of FZD6 and neural tube defects, such as failure of
neural tube closure along the entire body axis, suggesting the
importance of Fzd6 in directing cell migration and cell polarity
during brain morphogenesis.25 FZD6 is also important for nail
development, since homozygous frameshift mutations result in
the onset of a rare form of nail dysplasia. The mutations interfere
with the correct localization of the receptor at the cell membrane,
resulting in reduced or abrogated signal transduction.21 The
disease is characterized by the abnormal pattering and shape of
nails, consistent with a role in the control of PCP by Fzd6.
In agreement with the observations in patients bearing FZD6
mutations, FZD6-null mice manifest a phenotype characterized by
defects in cell migration and tissue polarization during organo-
genesis. FZD6-null mice are viable, but present a disorganized
orientation of the hair follicles and defects in the shaping of
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claws.21,26 Interestingly, studies conducted on FZD6 and FZD3
double knockout mice revealed a high level of redundancy
between the receptors: only abrogation of both FZD6 and FZD3
(but not the knockout of a single receptor) caused severe
embryonic defects in neural tube closure and planar orientation
of hair bundles on a subset of auditory and vestibular sensory
cells.27 Further studies on FZD6-null mice suggested that FZD6
might also be implicated in limiting the activation of platelets.28
In conclusion, the experimental evidence gathered so far
suggests that Fzd6 is required to direct the orientation and
migration of cells during organogenesis, probably via activation of
PCP signalling. One could speculate that reactivation of PCP in
adult tissues could contribute to the metastatic dissemination of
cancer cells. In the next chapter, we will review recent findings
strongly suggesting that Fzd6 does play a role in tumour
development and metastasis.
ROLE OF FZD6 AND NON-CANONICAL WNT SIGNALLING IN
CANCER
It is now well established that the canonical, β-catenin-dependent
wnt signalling pathway plays a major role in human cancer.29–31
Whether the PCP and non-canonical wnt pathways are also major
players in oncogenic transformation is still a matter of discussion.
There is some evidence though that cancer cells hijack the WNT
non-canonical signalling pathway to acquire the ability to migrate
and metastasize. For example, overexpression of WNT5a in
melanoma and gastric cancer causes increased cancer cell
migration and metastasis, but not β-catenin activation.32,33 Wnt5a
effects on cell migration and invasion are dependent on the
activation of protein kinase C (PKC) and other effectors of the
WNT/calcium pathway.33,34 Interestingly, Fzd6 has also been
shown to activate the WNT/calcium pathway and PKC in human
cells and in Xenopus.16,35 Wnt5a can, among other receptors, bind
to Fzd6 and both ligand and receptor are often overexpressed in
glioblastoma, suggesting that wnt5a and Fzd6 could potentially
cooperate to drive migration and invasion in these tumours.36,37
Several PCP core components are aberrantly expressed in
tumours, contributing to cancer cell proliferation and migration.
Overexpression of VANGL-1, a key component of the PCP
pathway, is associated with an increased risk of relapse in breast
cancer patients and its knockdown reduces breast cancer cell
migration.38 VANGL-2 overexpression was also linked to enhanced
tumour cell proliferation and poorer prognosis in breast cancer
through a mechanism that involves the JNK pathway.39 Notably,
mutations of VANGL1, like mutations of FZD6, are associated with
neural tube defects, suggesting that these two PCP effectors lie in
the same pathway and their aberrations might contribute to
cancer.40 Other core components of the PCP such as Celsr1,
Prickle1, Fzd3, Fzd7, Dvl2, Dvl3 and casein kinase 1 (CK1)-ε were
found upregulated in B lymphocytes of patients with chronic
lymphocytic leukaemia. PCP activation in these patients predicts a
worse prognosis and is mechanistically implicated in transen-
dothelial cell migration.41
FZD6 is critically required for the malignant transformation of
B-cells in Eμ-TCL1 mice that develop chronic lymphocytic
leukaemia. FZD6 expression drastically increases during leukae-
mogenesis, and its key role in B-cells transformation was elegantly
demonstrated by crossing Eμ-TCL1 with FZD6-null mice. Mice
harbouring FZD6 null alleles develop less leukaemia and have a
prolonged survival.42 Overall these studies suggest that core PCP
molecules are not only pivotal in regulating the migration of
cancer cells and the development of metastasis, but could also be
required for tumourigenesis.
In recent studies, it was investigated whether cues emanating
from the cancer associated stroma could regulate PCP. Luga and
colleagues demonstrated that exosomes secreted by cancer-
associated fibroblasts can instigate breast cancer cells to acquire a
motile phenotype by mobilizing PCP core components such as
FZD6, DVL1, VANGL1, PK1 and stimulating the autocrine secretion
of the non-canonical ligand Wnt11. Knockdown of DVL1, VANGL1,
PK1 inhibited cell motility and the migratory phenotype of highly
metastatic MDA-MB-231 cells, and lung metastasis were strongly
reduced in mice following depletion of Pk-1.43 In agreement with
these findings, our group has recently demonstrated that the
FZD6 gene is frequently amplified and overexpressed in triple
negative breast cancer, regulating the activity of the small GTPase
Rho, a key component of the non-canonical wnt pathway.44 Rho
and other members of the small GTPases family are key for
orchestrating the cytoskeleton rearrangements that occur during
cell migration, both in physiological and pathological conditions.
Rho signalling is essential to promote cancer metastasis by




G Corda and A Sala
3
Oncogenesis (2017), 1 – 7
regulating cell migration, extravasation and angiogenesis.45–47
Rho also plays a pivotal role in the PCP pathway: non-canonical
wnt signalling controls the convergent extension movements
through the activation of Rho and other GTPases during
morphogenesis.48 During amphibian gastrulation, PCP activated
downstream of Fzd7, Rho and wnt11 is implicated in fibronectin
matrix assembly, which in turn is fundamental for the correct
migration and polarization of embryonic cells during morphogen-
esis. Interestingly, we found that Fzd6 signalling is important for
the regulation of the actin cytoskeleton and extracellular
fibronectin matrix in breast cancer cells.44 Fibronectin is a large
glycoprotein involved in connecting cells with the extracellular
matrix during cell adhesion, growth and migration.49 Fibronectin
expression is also a hallmark of Epithelial to Mesenchymal
Transition, a process responsible for the metastatic behaviour of
cancer cells, modulated by wnt signalling.50 Fibronectin is also
implicated in the metastatic dissemination of cancer cells to the
bones and lungs of rodents51,52 and its expression inversely
correlates with survival in breast cancer patients.53 Thus, activation
of the PCP pathway through gene amplification and over-
expression of FZD6 could explain, at least in part, the high
metastatic propensity and the organ tropism of triple negative
breast cancer cells. Indeed, RNAi knockdown of FZD6 in MDA-
MB-231 triple negative breast cancer cells inhibited their motility
and caused reduction of bones and liver metastases, suggesting
that activation of the PCP pathway is critically important for
metastatic dissemination and tumour tropism in vivo.44
A summary of the validated and putative signalling pathways
downstream of Fzd6 is shown in Figure 3. FZD6 could also play a
role in other forms of human cancer since increased expression
has also been detected in liver, prostate, colorectal and squamous
cell carcinomas (Table 1)54–57.
FZD6 AND CANCER STEM CELLS
Cancer stem cells are thought to derive from normal counterparts
harbouring oncogenic mutations or transformed epithelial cells
that underwent epithelial to mesenchymal transition and acquired
a stem-like phenotype.58 In a previous study, our group has
demonstrated that the Fzd6 receptor is expressed on the surface
of stem-like cells in neuroblastomas. Fzd6high neuroblastoma cells
expressed high levels of mesenchymal markers such as Notch1and
Twist1, formed neurospheres with high efficiency in liquid culture,
were drug resistant and highly metastatic when injected
orthotopically into immunodeficient mice.23 These biological
features could be dependent on JNK activity since it is known
that this kinase regulates stem cell functions through activation of
the transcription factor AP-1 and the PCP pathway.24,59 A further
indication of the critical role played by Fzd6 in regulating cell
stemness is provided by a recent study in which Fzd6 was shown
to control the balance between self-renewal and survival of
hematopoietic stem cells. Ablation of FZD6 strongly inhibited the
repopulation of the hematopoietic compartment in the bone
marrow after irradiation and transplant of donor cells in mice.60 It
is intriguing to speculate that deregulation of Fzd6 signalling in
cancer stem cells might promote uncontrolled self-renewal,
Figure 3. Summary of validated and putative signalling pathways downstream of Fzd6. The question marks indicate molecular functions that
are only hypothetical and not fully demonstrated in previous studies.
Table 1. Summary of the studies in which increased expression of Frizzled 6 was detected in different cancers
Tumour type Activation mechanism Phenotype Reference
Breast cancer Gene amplification, overexpression Increased invasion and metastasis, predicts worse
prognosis in patients
44
Mesenchymal glioblastoma Overexpression Increased tumour growth in mice xenografts, predicts
worse prognosis in patients
62
Neuroblastoma Expression in cancer stem cells Drug resistance, increased tumour growth in mice




Progressive upregulation during CD5(+) B cells
leukaemogenesis
Reduced survival in mice 42
Hepatocellular carcinoma Overexpression High expression associated with lower tumour
differentiation
56
Prostate cancer Overexpression Not determined 54
Squamous cell carcinoma Overexpression Not determined 57
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homing and survival of metastatic cells in secondary organs. In
agreement with this hypothesis, FZD6 is highly expressed in brain
tumours containing mesenchymal, stem-like glioblastoma cells.
Patients with FZD6high mesenchymal glioblastomas have a higher
risk of recurrence and worse prognosis compared with other
glioblastoma molecular and cellular subtypes.61,62 Ectopic expres-
sion of FZD6 in proneural glioblastoma cells induced the
expression of stem cell markers and resulted in increased cell
proliferation and sphere formation in vitro and in vivo. Conversely,
ablation of FZD6 expression decreased proliferation of mesench-
ymal glioblastoma cells.62 Fzd6 controls glioblastoma cell survival
and proliferation through activation of the wnt/calcium pathway,
Nf-kB and Stat3, which are known to promote a mesenchymal,
stem-like state and aggressive behaviour of glioblastoma
cells.62–64
FZD6 AS A POTENTIAL PROGNOSTIC MARKER IN CANCER
Biomarkers are important as diagnostic tools, to predict disease
outcome and ultimately direct clinical decisions and therapeutic
strategies.65 An emblematic biomarker in oncology is HER2, whose
expression is critical in determining therapeutic strategies in
breast cancer.66 It would be important to identify new biomarkers
that predicted tumour recurrence. This would benefit patients by
allowing to discriminate those requiring aggressive treatments
from patients who can be spared chemo- or radio-therapy.67 The
identification of reliable markers to calculate the risk of metastatic
recurrence would be particularly desirable, since metastasis is the
primary cause of death in cancer patients. Tumour relapse occurs
when dormant cancer cells are reactivated after months or years
after chemotherapy and cancer stem cells markers have been
proposed to be good prognostic indicators for tumour recurrence
and metastasis.68–70 Cancer stem cells express membrane
transporters that promote the active excretion of cytotoxic drugs
and are resistant to drug killing, therefore are likely to constitute
the bulk of the dormant tumour cell population.71,72 In agreement
with the hypothesis that FZD6 could be a cancer stem cell marker,
high levels of FZD6 mRNA in neuroblastoma tumours indicate
poor patient prognosis and in lymph node negative breast cancer
high FZD6 expression predicts local and distant tumour
relapse.23,44 Positive Fzd6 immunostaining is correlated with
lower distant relapse-free survival of triple negative breast cancer
patients.23,44 FZD6 expression is also of prognostic value in
glioblastoma. Low expression of the transcription factor TCF4
coupled to high levels of FZD6 predict low survival of glioblastoma
patients.62 These findings suggest that expression of FZD6, like
other stem cell markers, could be potentially used as a prognostic
biomarker in different types of human cancer.
CONCLUDING REMARKS
Despite huge research efforts, no drugs targeting the wnt
signalling pathway have been yet approved for clinical use, but
clinical trials are ongoing in which new molecules targeting the
wnt pathway are being tested.73 For example, the monoclonal
antibody vantictumab is currently in phase 1 trials. The antibody
binds to FZDs 1, 2, 5, 7 and 8, and has been shown to reduce
activation of canonical wnt signalling in preclinical cancer
models.74 One could envisage that a naked or toxin conjugated
monoclonal antibody targeting Fzd6 could be developed to treat
cancers bearing high Fzd6 expression levels. In principle, such
antibody could be used to deplete rare subpopulations of drug
resistant, metastatic cancer stem cells within the tumour. The
phenotype of mice and humans carrying genetic inactivation and/
or mutation of Fzd6 is mild, mainly manifesting in the form of
defects in nail and hair development.21,26 Thus, it could be
predicted that antibodies targeting Fzd6 should have a good
therapeutic potential and be well tolerated, without affecting the
function of normal cells and tissues. Time will tell whether Fzd6
targeting has a future in cancer therapeutics.
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